Literature DB >> 21505063

mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients.

Anieta M Sieuwerts1, Bianca Mostert, Joan Bolt-de Vries, Dieter Peeters, Felix E de Jongh, Jacqueline M L Stouthard, Luc Y Dirix, Peter A van Dam, Anne Van Galen, Vanja de Weerd, Jaco Kraan, Petra van der Spoel, Raquel Ramírez-Moreno, Carolien H M van Deurzen, Marcel Smid, Jack X Yu, John Jiang, Yixin Wang, Jan W Gratama, Stefan Sleijfer, John A Foekens, John W M Martens.   

Abstract

PURPOSE: Molecular characterization of circulating tumor cells (CTC) holds great promise. Unfortunately, routinely isolated CTC fractions currently still contain contaminating leukocytes, which makes CTC-specific molecular characterization extremely challenging. In this study, we determined mRNA and microRNA (miRNA) expression of potentially CTC-specific genes that are considered to be clinically relevant in breast cancer. EXPERIMENTAL
DESIGN: CTCs were isolated with the epithelial cell adhesion molecule-based CellSearch Profile Kit. Selected genes were measured by real-time reverse transcriptase PCR in CTCs of 50 metastatic breast cancer patients collected before starting first-line systemic therapy in blood from 53 healthy blood donors (HBD) and in primary tumors of 8 of the patients. The molecular profiles were associated with CTC counts and clinical parameters and compared with the profiles generated from the corresponding primary tumors.
RESULTS: We identified 55 mRNAs and 10 miRNAs more abundantly expressed in samples from 32 patients with at least 5 CTCs in 7.5 mL of blood compared with samples from 9 patients without detectable CTCs and HBDs. Clustering analysis resulted in 4 different patient clusters characterized by 5 distinct gene clusters. Twice the number of patients from cluster 2 to 4 had developed both visceral and nonvisceral metastases. Comparing transcript levels in CTCs with those measured in corresponding primary tumors showed clinically relevant discrepancies in estrogen receptor and HER2 levels.
CONCLUSIONS: Our study shows that molecular profiling of low numbers of CTCs in a high background of leukocytes is feasible and shows promise for further studies on the clinical relevance of molecular characterization of CTCs. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21505063     DOI: 10.1158/1078-0432.CCR-11-0255

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  90 in total

1.  Medical oncology: clinical value of circulating tumor cells in breast cancer.

Authors:  Stefan Sleijfer; John A Foekens
Journal:  Nat Rev Clin Oncol       Date:  2011-11-01       Impact factor: 66.675

Review 2.  Molecular prescreening to select patient population in early clinical trials.

Authors:  Jordi Rodón; Cristina Saura; Rodrigo Dienstmann; Ana Vivancos; Santiago Ramón y Cajal; José Baselga; Josep Tabernero
Journal:  Nat Rev Clin Oncol       Date:  2012-04-03       Impact factor: 66.675

Review 3.  Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design.

Authors:  Jaap Verweij; Maja de Jonge; Ferry Eskens; Stefan Sleijfer
Journal:  Mol Oncol       Date:  2012-02-16       Impact factor: 6.603

Review 4.  Gene expression profiling and DNA methylation analyses of CTCs.

Authors:  Evi S Lianidou
Journal:  Mol Oncol       Date:  2016-02-05       Impact factor: 6.603

Review 5.  Materials and microfluidics: enabling the efficient isolation and analysis of circulating tumour cells.

Authors:  Joshua M Jackson; Małgorzata A Witek; Joyce W Kamande; Steven A Soper
Journal:  Chem Soc Rev       Date:  2017-07-17       Impact factor: 54.564

Review 6.  Challenges in circulating tumour cell research.

Authors:  Catherine Alix-Panabières; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2014-07-31       Impact factor: 60.716

Review 7.  Metastasis of circulating tumor cells: favorable soil or suitable biomechanics, or both?

Authors:  Ana Sofia Azevedo; Gautier Follain; Shankar Patthabhiraman; Sébastien Harlepp; Jacky G Goetz
Journal:  Cell Adh Migr       Date:  2015-08-27       Impact factor: 3.405

8.  Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance).

Authors:  Mark Jesus M Magbanua; Hope S Rugo; Denise M Wolf; Louai Hauranieh; Ritu Roy; Praveen Pendyala; Eduardo V Sosa; Janet H Scott; Jin Sun Lee; Brandelyn Pitcher; Terry Hyslop; William T Barry; Steven J Isakoff; Maura Dickler; Laura Van't Veer; John W Park
Journal:  Clin Cancer Res       Date:  2018-01-08       Impact factor: 12.531

Review 9.  Circulating tumour cells and cell-free DNA as tools for managing breast cancer.

Authors:  Leticia De Mattos-Arruda; Javier Cortes; Libero Santarpia; Ana Vivancos; Josep Tabernero; Jorge S Reis-Filho; Joan Seoane
Journal:  Nat Rev Clin Oncol       Date:  2013-05-28       Impact factor: 66.675

10.  Prognostic Relevance of Circulating Tumor Cells in Molecular Subtypes of Breast Cancer.

Authors:  M Banys-Paluchowski; H Schneck; C Blassl; S Schultz; F Meier-Stiegen; D Niederacher; N Krawczyk; E Ruckhaeberle; T Fehm; H Neubauer
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-03       Impact factor: 2.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.